



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/887,493-Conf. #7718
				Filing Date	June 22, 2001
				First Named Inventor	Gregor Cevc
				Art Unit	1654
				Examiner Name	S. D. Coe
Sheet	1	of	3	Attorney Docket Number	58069-CON (47126)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
SL	AA*	US-4,427,670	01-24-1984	Ofuchi, et al.	
	AB*	US-4,814,161	03-21-1989	Jinks, et al.	
	AC*	US-4,333,927	06-08-1982	Ofuchi, et al.	
	AD*	US-6,835,392-B2	12-28-2004	Hsu, et al.	
	AE*	US-6,562,370-B2	05-13-2003	Luo, et al.	
	AF*	US-6,582,724-B2	06-24-2003	Hsu, et al.	
	AG*	US-6,645,520-B2	11-11-2003	Hsu, et al.	
	AH*	US-6,586,000-B2	07-01-2003	Luo, et al.	
✓	AI*	US-2002/0048596-A1	04-25-2002	Cevc	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
SL	BA	WO-97/21428	06-19-1997	VESIFACT AG		✓
SL	BB	WO-95/35095	12-28-1995	YESSUM RESEARCH DEVELOPMENT COMPANY		
SL	BC	WO-81/02673	10-01-1981	Key Pharmaceuticals, Inc		
SL	BD	DE-40 26 833.0	08-24-1990		Priority document of BF	
SL	BE	EP 0 102 324	07-25-1983	CIBA-GEIGY AG		✓
SL	BF	EP 0 475 160	08-23-1991	G. Cevc		✓
SL	BG	DE 44 47 287	11-07-1996			✓
SL	BH	EP-0 995 435	04-26-2000	SENJU PHARMACEUTICAL CO., LTD.		
SL	BI	EP-0 355 095	08-04-1993	THE LIPOSOME COMPANY, INC.		
SL	BJ	EP-0 382 716	01-28-1998	WARNER-LAMBERT CO.		
SL	BK	HU-9903363	03-28-2000		English abstract; corresponds to US 2002/0048596	
SL	BL	HU-0104424	03-28-2002		English abstract; corresponds to WO 00/38653	
SL	BM	HU-0105400	05-29-2002		English abstract; corresponds to WO 00/44350	
SL	BN	WO-00/44350	08-03-2000			
SL	BO	WO-00/38653	07-06-2000	IDEA INNOVATIVE DERMALE APPLICATIONEN GMBH		
SL	BP	WO-92/22292	12-23-1992	SCHWARZ PHARMA AG	English abstract	
SL	BQ	WO-00/25822	05-11-2000	John C. GASELA, et al.		
SL	BR	WO-02/11683	02-14-2002	DOW PHARMACEUTICAL SCIENCES		

Examiner Signature	<i>William D. Coe</i>	Date Considered	6-26-06
-----------------------	-----------------------	--------------------	---------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/887,493-Conf. #7718
				Filing Date	June 22, 2001
				First Named Inventor	Gregor Cevc
				Art Unit	1654
				Examiner Name	S. D. Coe
Sheet	2	of	3	Attorney Docket Number	58069-CON (47126)

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
SL	BS	WO-01/12155		02-22-2001	LIPOCINE, INC.		
SL	BT	WO-02/07767-A2		01-31-2002	ALCON UNIVERSAL LTD.		
SL	BU	WO-98/07414		02-26-1998	RESEARCH TRIANGLE PHARMACEUTICALS LTD.		
SL	BV	WO-00/13684		03-16-2000	LOMA LINDA UNIVERSITY MEDICAL CENTER		
SL	BW	WO-01/01963		01-11-2001	IDEA AG		
SL	BQ	WO-96/29999		10-03-1996	HEXAL AG	English abstract	
SL	BY	WO-94/26257		11-24-1994	LTS LOHMANN THERAPIE-SYSTEME GMBH & CO.	English abstract	
SL	BZ	WO-00/50007		08-31-2000	LIPOCINE, INC.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
* SL	CA	Ulmans Encyklopadie der technischen Chemie, Autoren- und Sachregister, pp. 245-246. 4th ed.	✓
* SL	CB	Prof. Dr. Jurgen Falbe, et al., "Rompp Chemie Lexikon," p.3168.	
* SL	CC	Encyclopedia of Chemical Technology, Third Edition, pp. 835-836.	
* SL	CD	Kurt H. Bauer, et al., "Lehrbuch der Pharmazeutischen Technologie," p. 464, 1999.	
* SL	CE	Dr. Ursula Schoffing, Trier, "Ein Lehrbuch der Galenik Fur Theorie und Praxis," p. 459, 1998.	
* SL	CF	B. Halliwell and J. M.C. Gutteridge, "Free Radicals in Biology and Medicine," Third Edition, p. 925.	
* SL	CG	Klare S. Markley, "Fatty Acids: Their Chemistry, Properties, Production, and Uses," Second Completely Revised and Augmented Edition, Part 1, p. 703, 1960.	
* SL	CH	Klare S. Markley, "Fatty Acids: Their Chemistry, Properties, Production, and Uses," Second Completely Revised and Augmented Edition, Part 2, pp. 1473-1474, 1961.	
* SL	CI	Dr. Hermann Pardun, "Die Pflanzenlecithine: Gewinnung, Eigenschaften, Verarbeitung und Anwendung pflanzlicher Phosphatidpraparate," Verlag fur chemische Industrie H. Ziolkowsky KG, Augsburg, p. 552, 1988.	
* SL	CJ	Gregory Gregoriadis, "Drug Carriers in Biology and Medicine," Academic Press, p. 361-361, 1979.	
* SL	CK	Gregor Cevc, "Phospholipids Handbook," Marcel Dekker, Inc., p. 878, 1993.	
* SL	CL	"The detection of oxidation in liposome preparations," <i>Biochim. Biophys. Acta</i> , 210, pp. 486-489, 1970.	
* SL	CM	Dov Lichtenberg, "Liposomes: Preparation, Characterization, and Preservation," <i>Methods of Biochemical Analysis</i> , Vol. 33, pp. 337, 359-360..	

Examiner Signature	<i>Andrew D. Coe</i>	Date Considered	6-26-06
-----------------------	----------------------	--------------------	---------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/887,493-Conf. #7718
				Filing Date	June 22, 2001
				First Named Inventor	Gregor Cevc
				Art Unit	1654
				Examiner Name	S. D. Coe
Sheet	3	of	3	Attorney Docket Number	58069-CON (47126)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
* <i>SC</i>	CN	Dr. Ernst Mutschler, "Arzneimittel-wirkungen: Lehrbuch der pharmakologie und Toxikologie," 1991.	✓
* <i>SC</i>	CO	Dr. Rainer H. Muller, et al., "Pharmazeutische Technologie: Moderne Arzneiformen," 1998.	✓
* <i>SC</i>	CP	Phospholipids in Cosmetics and Pharmaceuticals, Rhone-Poulenc Rorer, Nattermann Phospholipid GMBH, p. 9/51, April 1997.	
* <i>SC</i>	CQ	H. Sucker, et al., "Pharmazeutische Technologie," pp. 644-649, 1978.	✓
* <i>SC</i>	CR	H. Sucker, et al., "Pharmazeutische Technologie," pp. 288, 293-300, 1978.	✓
* <i>SC</i>	CS	H. Sucker, et al., "Pharmazeutische Technologie," pp. 312-315, 1978.	✓
* <i>SC</i>	CT	H. Sucker, et al., "Pharmazeutische Technologie," pp. 315-320, 1978.	✓

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Samuel D. Coe</i>	Date Considered	6-26-06
-----------------------	----------------------	--------------------	---------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	09/887,493-Conf. #7718	
			Filing Date	June 22, 2001	
			First Named Inventor	Gregor Cevc	
			Art Unit	1655	
			Examiner Name	S. D. Coe	
Sheet	1	of	1	Attorney Docket Number	58069CON(47126)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SC	CA	Ullmann's Encyclopedia of Industrial Chemistry, 4th edition, Vol. 18, pp. 57.	✓

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Susan D Coe</i>	Date Considered	6-26-06
-----------------------	--------------------	--------------------	---------